| Missing (N=109) |
PD-L1 TPS (N=85) |
P-value | |
|---|---|---|---|
| Age(years) | |||
| Mean (SD) | 63.8 (7.79) | 63.7 (8.57) | 0.432 |
| Median [Min, Max] | 66.0 [35.0, 78.0] | 64.0 [33.0, 80.0] | |
| Sex | |||
| FeMale | 12 (11.0%) | 9 (10.6%) | 1 |
| Male | 97 (89.0%) | 76 (89.4%) | |
| Smoking | |||
| No | 30 (27.5%) | 18 (21.2%) | 0.396 |
| Yes | 79 (72.5%) | 67 (78.8%) | |
| Pathologic subtype | |||
| Non squamous | 53 (48.6%) | 53 (62.4%) | 0.0783 |
| Squamous | 56 (51.4%) | 32 (37.6%) | |
| PFS(months) | |||
| Mean (SD) | 12.4 (7.58) | 16.7 (9.42) | 0.32 |
| Median [Min, Max] | 11.7 [0.367, 36.9] | 14.9 [0.600, 37.4] | |
| OS(months) | |||
| Mean (SD) | 15.9 (9.18) | 19.5 (9.01) | 0.326 |
| Median [Min, Max] | 14.9 [0.367, 38.3] | 19.4 [1.23, 39.3] | |
| Clinical benefit | |||
| DCB | 87 (79.8%) | 71 (83.5%) | 0.586 |
| NDB | 21 (19.3%) | 14 (16.5%) | |
| Unknown | 1 (0.9%) | 0 (0%) | |
| LDH | |||
| Mean (SD) | 272 (215) | 202 (91.4) | 0.212 |
| Median [Min, Max] | 203 [96.0, 1660] | 175 [66.7, 560] | |
| Missing | 4 (3.7%) | 2 (2.4%) | |
| NLR | |||
| Mean (SD) | 4.36 (2.62) | 3.41 (2.07) | 0.325 |
| Median [Min, Max] | 3.72 [1.04, 16.3] | 2.86 [1.15, 14.0] | |
| Missing | 1 (0.9%) | 1 (1.2%) | |
| Bone metastasis | |||
| No | 60 (55.0%) | 50 (58.8%) | 0.703 |
| Yes | 49 (45.0%) | 35 (41.2%) | |
| Brain metastasis | |||
| No | 96 (88.1%) | 66 (77.6%) | 0.0807 |
| Yes | 13 (11.9%) | 19 (22.4%) | |
| Liver metastasis | |||
| No | 91 (83.5%) | 76 (89.4%) | 0.33 |
| Yes | 18 (16.5%) | 9 (10.6%) | |
| Pleura metastasis | |||
| No | 77 (70.6%) | 63 (74.1%) | 0.708 |
| Yes | 32 (29.4%) | 22 (25.9%) | |
| Lymph metastasis | |||
| No | 44 (40.4%) | 38 (44.7%) | 0.645 |
| Yes | 65 (59.6%) | 47 (55.3%) |